Results 251 to 260 of about 564,426 (377)

Advantages of 3D CT based treatment planning in female patients with Hodgkin lymphoma compared to conventional non CT planned mantle technique

, 1998
T. Vuong, William Parker, Palma Fava, D. Parmar, Horacio Patrocinio, E. B. Podgoršak   +5 more
openalex   +1 more source

Non-Hodgkin lymphoma among young adults with and without AIDS in Italy [PDF]

, 2001
Luigino Dal Maso, Giovanni Rezza, Paola Zambon, Giovanna Tagliabue, Emanuele Crocetti, Marina Vercelli, Roberto Zanetti, Fabio Falcini, Giuseppe Tonini, Lucìa Mangone, Vincenzo De Lisi, Stefano Ferretti, ­Rosario ­Tumino, Giorgio Stanta, Susanna Vitarelli, Diego Serraino, Silvia Franceschi   +16 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Global burden and trends of childhood non-Hodgkin lymphoma from 1990 to 2021. [PDF]

Front Pediatr
Xie J, Xu JS, Huang JW, Zheng YS.
europepmc   +1 more source

Epstein-Barr virus (EBV) infection is predictive of central nervous system (CNS) involvement in AIDS-related systemic non-Hodgkin lymphoma.

, 1999
Antonella Cingolani, Roberto Gastaldi, Maria Letizia Giancola, Francesco Pierconti, Edoardo Pescarmona, Andrea De Luca, Carla Mazzone, Andrea Antinori, Luigi Maria Larocca   +8 more
openalex   +1 more source

Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma [PDF]

, 2001
Luis F. Porrata, Morie A. Gertz, David J. Inwards, Mark R. Litzow, Martha Q. Lacy, Ayalew Tefferi, Dennis A. Gastineau, Angela Dispenzieri, Stephen M. Ansell, Ivana N. Micallef, Susan M. Geyer, Svetomir N. Markovic   +11 more
openalex   +1 more source

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma

Cancer Science, EarlyView.
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara, Isao Yoshida, Takuro Ishiguro, Katsuya Fujimoto, Junya Kuroda, Toshiki Uchida, Ryusuke Yamamoto, Yoshiaki Ogawa, Yasushi Hiramatsu, Toshiro Ito, Seiichiro Katagiri, Tomonori Nakazato, Kazumi Suzukawa, Kenzo Kinami, Mi Zhou, Eiju Negoro   +15 more
wiley   +1 more source

The Non-Hodgkin's Lymphomas [PDF]

CA: A Cancer Journal for Clinicians, 1985
Renee H. Jacobs, John E. Ultmann
openaire   +3 more sources

The Role of Histone Methyltransferase SETDB1 in Normal and Malignant Hematopoiesis

Cancer Science, EarlyView.
In this review, we discuss the role of SETDB1 in gene regulation, including an overview of its structural features and key cofactors. We also highlight the lineage‐specific roles of SETDB1 in both normal hematopoietic processes and hematological malignancies, emphasizing its function as an immune checkpoint molecule that suppresses natural killer cell ...
Yu‐Hsuan Chang, Susumu Goyama
wiley   +1 more source

A Retrospective Study on the Incidence, Mortality, and Risk Factors of Hodgkin Lymphoma in Pakistan. [PDF]

Cureus
Shafiq S, Fatima SN, Zahid A, Khattak T, Abbasi SK, Mumtaz MR.   +5 more
europepmc   +1 more source